Collegium Pharmaceutical has expanded its footprint in ADHD and pain management through acquisitions and proprietary abuse-deterrent technologies. The company posted a significant rebound in operating income and cash flow in 2025, supported by its diversified product lineup including Jornay PM and Xtampza ER. However, ongoing regulatory scrutiny on opioid marketing, industry-wide pricing pressures, and substantial indebtedness constrain future profitability and operational flexibility. Monitoring payor reimbursement trends, legal developments, and supply chain resilience will be critical for assessing its growth trajectory.